2025
Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Magvanjav O, Bergwitz C. Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease. JCEM Case Reports 2025, 3: luaf031. PMID: 40110572, PMCID: PMC11920620, DOI: 10.1210/jcemcr/luaf031.Peer-Reviewed Original ResearchBone-specific alkaline phosphataseGiant cell tumorCell tumorsPaget's diseaseCalcitriol-mediated hypercalcemiaOsteoclast-like giant cellsDose of denosumabTreated with bisphosphonatesReduced tumor sizeOne-time doseElevated calcitriolParathyroid autonomyPolyostotic PDBStromal mononuclear cellsPelvic massSymptomatic hypercalcemiaTumor regrowthTumor sizeParathyroid hormoneKidney injuryNormal calciumMononuclear cellsDenosumabHypercalcemiaLong-term management optionThe Association of Gender in the Management and Prognosis of Vertebral and Sacral Chordoma: A SEER Analysis
Elsamadicy A, Sayeed S, Sherman J, Serrato P, Ghanekar S, Lo S, Sciubba D. The Association of Gender in the Management and Prognosis of Vertebral and Sacral Chordoma: A SEER Analysis. Journal Of Clinical Medicine 2025, 14: 1737. PMID: 40095791, PMCID: PMC11901273, DOI: 10.3390/jcm14051737.Peer-Reviewed Original ResearchFive-year survivalICD-O-3 codesNeo-adjuvant radiotherapyPredictors of survivalCancer Registry databaseRetrospective cohort studyAssociated with survivalICD-O-3SEER analysisTumor characteristicsSacral chordomaTumor sizeTumor locationMale patientsPatient demographicsSkull baseOsseous tumorsTreatment utilizationEnd ResultsRegistry databaseChordomaCohort studyTreatment characteristicsTumorPatientsThe development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas
Jester N, Singh M, Lorr S, Tommasini S, Wiznia D, Buono F. The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas. Scientific Reports 2025, 15: 5918. PMID: 39966622, PMCID: PMC11836447, DOI: 10.1038/s41598-025-88589-x.Peer-Reviewed Original ResearchConceptsGround-truth datasetDice scoreVestibular schwannomaImage processing accuracyVolumetric analysisML-based algorithmsMeasuring tumor sizeMean dice scoreAuto-segmentation toolAccurate AIAI modelsTumor sizeTumor modelVS tumorsTumor growthTesting stageAI-LTumorImage processing softwareClinical practicePatient recruitmentProcessing softwareSchwannomaDatasetManual segmentation
2024
Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment
Singh K, Abdou H, Panth N, Chiang V, Buono F, Schwartz N, Mahajan A. Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment. Otology & Neurotology 2024, 46: 196-200. PMID: 39792983, DOI: 10.1097/mao.0000000000004392.Peer-Reviewed Original ResearchConceptsTumor volume assessmentABC/2 methodVestibular schwannomaVolume assessmentPlanimetry methodTumor volumeTumor volume changesFollow-up scansOverestimate tumor volumePatients' quality of lifeTumor sizeRetrospective reviewIntracranial tumorsImprove clinical decision makingSubgroup analysisVolumetric assessmentTumorClinical decision makingQuality of lifePatients' qualityPatientsClinical settingPlanimetryImaging techniquesPositive correlationRace and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Hortobagyi G, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal Of The National Cancer Institute 2024, djae314. PMID: 39656951, DOI: 10.1093/jnci/djae314.Peer-Reviewed Original ResearchInvasive disease-free survivalHormone receptor-positiveRecurrence scoreRxPONDER trialClinical outcomesReceptor-positiveBreast cancerHER2-negative breast cancerNode-positive breast cancerDisease-free survivalMultivariate Cox modelBreast cancer outcomesBody mass indexHER2-negativePositive nodesTumor sizeSurvival outcomesClinicopathological characteristicsClinical characteristicsMass indexSelf-reported race/ethnicityCancer outcomesSecondary outcomesNHB womenTreatment efficacyEPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS
Alanya H, Yalcin K, Hilton B, Gultekin B, Mishra-Gorur K, McGuone D, Gunel M, Omay S, Erson-Omay Z. EPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS. Neuro-Oncology 2024, 26: viii9-viii9. PMCID: PMC11553213, DOI: 10.1093/neuonc/noae165.0034.Peer-Reviewed Original ResearchGH-secreting pituitary adenomasWhole-exome sequencingPituitary adenomasGNAS mutationsCopy number variationsSporadic GH-secreting pituitary adenomasGrowth hormone (GH)-secreting pituitary adenomasGenomic profilingGrowth hormone secreting pituitary adenomaSecreting pituitary adenomasBlood samplesComprehensive genomic characterizationSomatic GNAS mutationsSingle nucleotide variantsMatched blood samplesGenomic instabilityAssessment of genomic instabilityStatistically significant differenceTumor sizeClinical featuresTumor samplesClinical dataTumorExome sequencingBrain tumorsRADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING
Zhu J, Hager T, Chadha S, Sritharan D, Weiss D, Hossain S, Osenberg K, Moore N, Aneja S. RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING. Neuro-Oncology 2024, 26: viii74-viii74. PMCID: PMC11553274, DOI: 10.1093/neuonc/noae165.0296.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaWhole-brain radiotherapyTreated with chemotherapyOverall survivalHigh-risk groupPatient phenotypesCentral nervous system lymphomaPCNSL treatmentRisk of neurocognitive side effectsImaging biomarkersC-statisticOne-year OSTwo-year OSNervous system lymphomaAssociated with improved outcomesLog-rank testNeurocognitive side effectsTime-dependent AUCBrain radiotherapySystem lymphomaTumor volumeTumor sizeRisk stratificationAnalyses assessed differencesSub-analysisLiving on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff
Udelsman B, Bedrosian C, Kawaguchi E, Ding L, Wallace W, Rosenberg G, Harano T, Wightman S, Atay S, Kim A, Woodard G. Living on the Edge: Role of Adjuvant Therapy After Resection of Primary Lung Cancer Within 2 Millimeters of a T-Stage Cutoff. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39521371, DOI: 10.1016/j.jtcvs.2024.10.053.Peer-Reviewed Original ResearchNon-small cell lung cancerSystemic therapyOverall survivalT stageTumor sizeResected non-small cell lung cancerLung cancerNational Cancer Database of patientsResection of primary lung cancerOutcomes of systemic therapyPathologic tumor sizeNational Cancer DatabaseAdjuvant therapy useUse of systemic therapyPrimary lung cancerResection of tumorsCell lung cancerAssociated with decreased ratesDatabase of patientsRetrospective cohort studyTumor size distributionDownstaged patientsNodal involvementUnder-stagingAdjuvant therapyAssessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Generali D, Rocca A, Strina C, Milani M, Fiorino E, Cervoni V, Azzini C, Saracino A, Ciliberto I, Ziglioli N, Alberio M, Giudici F, Dester M, Ciani O, Fornaro G, Aguggini S, Dreezen C, Pronin D, Ende S. Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients. Heliyon 2024, 10: e39485. PMID: 39553665, PMCID: PMC11564935, DOI: 10.1016/j.heliyon.2024.e39485.Peer-Reviewed Original ResearchLow-risk tumorsHigh-risk tumorsRisk tumorsOverall survivalBreast cancerFollow-upPrognostic performanceHigh-risk BC patientsIntermediate-risk breast cancerLong-term prognostic abilitySingle-center prospective cohort studyPathologic tumor characteristicsProgesterone receptor-positiveSingle-center prospective cohortMedian follow-upBreast cancer patientsGenomic riskProspective cohort studyCox regression modelsPersonalize treatment choicesNodal statusReceptor statusReceptor-positiveTumor characteristicsTumor sizeImpact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy
Hicks D, Chen H, Kim J, Tressel L, Wallington D, Becht K, Johung K, Young M, Feghali K, de Jong D, Chen Z, Carlson D, Park H. Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s162-s163. DOI: 10.1016/j.ijrobp.2024.07.2188.Peer-Reviewed Original ResearchPlanning target volumeInternal target volumeBiology-guided radiotherapyStereotactic body radiotherapyGross tumor volumeTarget volumeCT simulationOptimal patient selectionPET evaluationStereotactic body radiotherapy planLung target volumesPatient selectionPTV edgesLung casesBgRTPET-CTTumor sizeTumor volumeRadiotherapyCase 2PET dataLungActivity concentrationsPatientsConsistent with resultsInvestigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive useUse of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression modelPartial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis
Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. Life 2024, 14: 661. PMID: 38929645, PMCID: PMC11204969, DOI: 10.3390/life14060661.Peer-Reviewed Original ResearchOverall survivalHepatocellular carcinomaPartial hepatectomyTumor sizeAssociated with inferior overall survivalEarly-stage hepatocellular carcinomaEarly-stage HCC patientsInferior overall survivalHepatocellular carcinoma patientsAblation armCarcinoma patientsAblation therapyNo significant differenceTreatment regimensHCC patientsEmulated target trialSurgical proceduresEffect of ablationHepatectomyPatientsCompare treatment effectsClinical treatmentSignificant differencePropensity scoreLogistic regressionThe Malignant Potential of Ovarian Steroid Cell Tumors Revisited
Fadare O, Fard E, Bhargava R, Desouki M, Hanley K, Ip P, Li J, Lu B, Medeiros F, Ng J, Parkash V, Pinto A, Quick C, Skala S, Tokuyama M, Turashvili G, Wei C, Xing D, Zheng W, Soong T, Howitt B. The Malignant Potential of Ovarian Steroid Cell Tumors Revisited. The American Journal Of Surgical Pathology 2024, 48: 570-580. PMID: 38512100, DOI: 10.1097/pas.0000000000002201.Peer-Reviewed Original ResearchSteroid cell tumorPredictor of patient outcomeDied of diseaseTumor hemorrhageTumor necrosisClinicopathological predictorsTumor sizeMalignant potentialCell tumorsAssociated with reduced recurrence-free survivalCases of steroid cell tumoursOvarian steroid cell tumorTumor size >4Median tumor sizeMicroscopic tumour necrosisMedian patient agePredictors of recurrenceRecurrence-free survivalMulti-institutional cohortPatient outcomesStage IA casesAssociated with recurrenceHigh-power fieldsLog-rank testUnivariate Cox modelImmune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation
Khalil M, Fishman A, Komorowski A, Franco I, Grasso M. Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation. BJUI Compass 2024, 5: 604-610. PMID: 38751949, PMCID: PMC11090768, DOI: 10.1002/bco2.335.Peer-Reviewed Original ResearchImmune check point inhibitorsHigh-grade upper tract urothelial carcinomaUpper tract urothelial carcinomaMetastasis-free survival ratesGroup 2Group 1Survival rateUrothelial carcinomaSurvival outcomesMedian follow-up periodImpact of clinical characteristicsCheck-point inhibitorsImmune checkpoint inhibitorsEndoscopically treated patientsInitial tumor sizeImprove survival outcomesOverall survival rateKaplan-Meier analysisFollow-up periodImproved survival ratesCheckpoint inhibitorsPoint inhibitorsExtirpative surgeryTumor sizeClinical characteristics
2023
Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study. Journal Of The American College Of Radiology 2023, 21: 295-308. PMID: 37922972, DOI: 10.1016/j.jacr.2023.10.017.Peer-Reviewed Original ResearchCancer-specific mortalityCancer-specific deathSurgical resectionSocial determinantsPortal hypertensionTumor sizeTreatment characteristicsSmall HCCAsian raceDisease factorsMultivariable Cox regression modelsSEER-Medicare studyChronic kidney diseaseHigh-volume centersLarger tumor sizeCox regression modelSignificant protective factorCause mortalityClinical factorsEsophageal varicesIndependent predictorsSEER-MedicareKidney diseaseVolume centersProcedure yearClinical Validation of Artificial Intelligence-Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection.
Raciti P, Sue J, Retamero J, Ceballos R, Godrich R, Kunz J, Casson A, Thiagarajan D, Ebrahimzadeh Z, Viret J, Lee D, Schüffler P, DeMuth G, Gulturk E, Kanan C, Rothrock B, Reis-Filho J, Klimstra D, Reuter V, Fuchs T. Clinical Validation of Artificial Intelligence-Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection. Archives Of Pathology & Laboratory Medicine 2023, 147: 1178-1185. PMID: 36538386, DOI: 10.5858/arpa.2022-0066-oa.Peer-Reviewed Original ResearchConceptsDiagnostic accuracyProstate biopsy specimensProstate cancer detectionProstate cancer diagnosisCancer diagnosisUS Food and Drug Administration authorityWhole slide imagesGenitourinary subspecialistsTumor sizeHistological gradeApplication of artificial intelligenceBiopsy specimensProstateSimulated clinical settingClinical validationAssessment of tissueClinical settingClinical applicationCancerCancer detectionDiagnosisPathologistsDeep learning-based systemDigital whole slide imagesLearning-based systemAssociation of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival
Zhang D, Xi Y, Boffa D, Liu Y, Nogueira L. Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival. JAMA Oncology 2023, 9: 1214-1220. PMID: 37498574, PMCID: PMC10375383, DOI: 10.1001/jamaoncol.2023.2144.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall survivalWorse overall survivalLung cancerNSCLC surgeryCohort studyHazard ratioSurgical resectionNSCLC resectionLong-term overall survivalNational Cancer DatabaseLung cancer surgeryLymph node involvementCell lung cancerHealth insurance typeHealth hazardsHospital dischargeNode involvementCancer surgeryStudy endTumor sizeCancer DatabaseInsurance typeHigh riskUnexposed individualsSurgical management of peritoneal metastasis: Opportunities for pharmaceutical research
Wientjes M, Lu Z, Chan C, Turaga K, Au J. Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research. Journal Of Controlled Release 2023, 361: 717-726. PMID: 37574051, PMCID: PMC10560040, DOI: 10.1016/j.jconrel.2023.08.017.Peer-Reviewed Original ResearchConceptsCytoreductive surgeryIntraperitoneal chemotherapyPatient ascitesPeritoneal metastasisPM patientsTreatment of peritoneal metastasesPresence of ascitesAccumulation of ascitesProtein bindingTumor locationTumor sizeSystemic treatmentAscites samplesAscitesClinical advancesAAG concentrationPatient managementTreatment outcomesPaclitaxelVariable efficacyPatientsProteomic analysisFree fractionAscites proteinsHyperthermic temperaturesDoes Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery?
Cairns A, Chagpar A, Dupont E, Levine E, Gass J, Chiba A, Ollila D, Howard-McNatt M. Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery? Annals Of Surgical Oncology 2023, 30: 6053-6058. PMID: 37505353, DOI: 10.1245/s10434-023-13884-8.Peer-Reviewed Original ResearchConceptsPreoperative magnetic resonance imagingMagnetic resonance imagingExtensive intraductal componentMargin statusPositive marginsTumor sizeTumor factorsMedian tumor sizeBreast conserving surgeryBreast cancer managementInvasive lobular histologyNeoadjuvant chemotherapyLobular histologyIntraductal componentMedian ageMulticenter trialPatient agePalpable tumorsPatient factorsShave marginsNegative marginsResultsA totalAssociated FactorsBreast cancerUS Centers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply